Could an immunotherapy combo replace harsh chemo for head and neck cancer?

NCT ID NCT03529422

Ongoing Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether combining the immunotherapy drug durvalumab (Imfinzi) with radiation therapy can effectively treat intermediate-risk head and neck cancer after surgery, while causing fewer serious side effects than the standard cisplatin-based chemo-radiation. The study enrolls adults with certain head and neck cancers and gives them durvalumab every three weeks for six cycles along with six weeks of daily radiation. Researchers track how many patients remain cancer-free at three years and monitor for severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (Imfinzi) and intensity-modulated radiotherapy (IMRT)
What this could lead to: If successful, this combination could offer a less toxic alternative to standard chemotherapy plus radiation for head and neck cancer patients, potentially improving quality of life while maintaining cure rates.
What could go wrong: This is a small, early-phase study (18 participants) with no control group, so results may not apply broadly. Durvalumab is not yet approved for head and neck cancer and can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIGESTIVE ORGANS--DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system disorder head and neck squamous cell carcinoma laryngeal disorder lip and oral cavity carcinoma lymphoid interstitial pneumonia Mouth Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIGESTIVE ORGANS--DISEASES LARYNX LIP ORAL CANCER

Contacts and locations

Locations

Medical University of South Carolina - Hollings Cancer Center

Charleston, South Carolina, 29425, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
University Of Alabama At Birmingham

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.